# Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.

> **NCT02097810** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 84 (actual)

## Conditions studied

- Locally Advanced Solid Tumors
- Metastatic Solid Tumors

## Interventions

- **DRUG:** Entrectinib

## Key facts

- **NCT ID:** NCT02097810
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-28
- **Primary completion:** 2020-06-02
- **Final completion:** 2020-06-02
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2021-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02097810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02097810, "Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT02097810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*